Pharma stocks to buy: Cipla, Lupin, among 5 stocks with upside potential of up to 12%

 12 Jun 2025 08:14 AM

Brokerages spot bullish signals in pharma stocks, picking five candidates poised for up to 12% gains.

Market Trading Guide: Lupin, Mastek are among 5 stocks to buy on Thursday. Potential upside up to 7%

 11 Jun 2025 09:00 PM

Indian headline indices closed with modest gains on Wednesday as IT strength offset banking weakness. Analysts maintain a bullish view, citing a golden crossover and support at 24,850, with near-term targets set around 25,350.

Lupin: Co Receives Tentative Approval from U.S. FDA for Oxcarbazepine ER Tablets

 07 Jun 2025 05:07 PM

Lupin: Co Receives Tentative Approval from U.S. FDA for Oxcarbazepine ER Tablets

Lupin: Company Achieves Significant Relief In Mirabegron Legal Matter

 05 Jun 2025 09:36 AM

Lupin: Company Achieves Significant Relief In Mirabegron Legal Matter

Lupin, Kalpataru Projects among Axis Securities’ top 7 SMID picks for June

 03 Jun 2025 01:57 PM

The recent market rally, driven by robust Q4 earnings, easing geopolitical tensions, and positive FY26 macro outlook, was supported by renewed investor risk appetite.

Novartis offers payment plan for high-cost heart medicine

 27 May 2025 12:20 AM

Novartis introduces a financing scheme with Pine Labs for its cholesterol-lowering drug, Sybrava (inclisiran), in India, aiming to broaden access by offering zero-interest EMI options. This strategy addresses the drug's high cost, previously ₹1.2 lakh per injection, and involves partnerships with Mankind Pharma, JB Pharma, and Lupin to expand market reach.

LUPIN: CO ANNOUNCES PRESENTATION OF PHASE 1 DATA ON LNP7457 (PRMT5 INHIBITOR) AT THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY - ANNUAL MEETING 2025

 26 May 2025 09:25 PM

LUPIN: CO ANNOUNCES PRESENTATION OF PHASE 1 DATA ON LNP7457 (PRMT5 INHIBITOR) AT THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY - ANNUAL MEETING 2025

Lupin inks licensing deal to supply biosimilar ranibizumab in Latin America

 26 May 2025 02:12 PM

Lupin, an Indian drug maker, partners with SteinCares. The agreement focuses on ranibizumab's commercialisation. Latin America, excluding Mexico and Argentina, is the target. SteinCares will handle regulatory aspects. Lupin will manufacture the biosimilar drug. This collaboration aims to improve retinal care access.

LUPIN: CO AND STEINCARES ENTER INTO LICENSE AND SUPPLY AGREEMENT FOR RANIBIZUMAB IN LATIN AMERICA

 26 May 2025 10:17 AM

LUPIN: CO AND STEINCARES ENTER INTO LICENSE AND SUPPLY AGREEMENT FOR RANIBIZUMAB IN LATIN AMERICA

LUPIN: CO UNIT LUPIN INC. USA, CONVERTED THE LOAN OF USD 41M AND OUTSTANDING INTEREST OF USD 3.3M FROM DEBT TO EQUITY TO LUPIN ONCOLOGY INC., USA

 23 May 2025 06:23 PM

LUPIN: CO UNIT LUPIN INC. USA, CONVERTED THE LOAN OF USD 41M AND OUTSTANDING INTEREST OF USD 3.3M FROM DEBT TO EQUITY TO LUPIN ONCOLOGY INC., USA